ARTICLE | Product Development
Pipeline setbacks add to Novo’s challenges
Five discontinuations include two assets tied to recent M&A deals
August 7, 2025 12:33 AM UTC
Novo Nordisk announced a series of program terminations and trial failures Wednesday, including two that stemmed from some of the pharma’s most recent acquisitions.
As part of its 2Q25 earnings announcement, Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) disclosed setbacks for five clinical programs: two that failed Phase II trials and three discontinued due to portfolio considerations. ...